K080918 page1/2

510(k) SUMMARY

APR 23 2008

Orthocord #2-0 suture with or without needles

Submitter's Name and

Address:

DePuy Mitek

a Johnson & Johnson company

325 Paramount Drive Raynham, MA 02767

Contact Person

Kristine Christo

Regulatory Affairs Project Lead

DePuy Mitek

a Johnson & Johnson company

325 Paramount Drive Raynham, MA 02767

Telephone:

508 828-3359

Facsimile:

508-977-6955

e-mail:

KChristo@Dpyus.jnj.com

Name of Medical Device

Classification Name:

Non-absorbable poly(ethylene terephthalate)

surgical suture; and

Suture, Surgical, Absorbable, Polydioxanone

Common/Usual Name:

Suture

Proprietary Name:

Orthocord suture

Orthocord #2-0 suture is substantially equivalent to:

Substantial Equivalence

Orthocord #2 suture (K040004, K043298) manufactured by Mitek; Mini OA+ / Minilok OA+ (K071622) manufactured by Mitek and

Fiberwire (K021434) manufactured by Arthrex

Device Classification

Sutures, classified by the FDA, are Class II Medical Devices. PDS Suture carries an FDA product code NEW, and is classified as absorbable surgical suture, polydiaxanone under 21 CFR 878.4840. Polyethylene suture carries an FDA product code GAT, and is classified

under 21 CFR 878.5000.

Device Description

ORTHOCORD suture is a synthetic, sterile, braided composite suture composed of dyed (D&C Blue #6 or D&C Violet #2) absorbable polydioxnone (PDS) and un-dyed non-absorbable polyethylene. The partially absorbable suture is coated with a copolymer of 90%

caprolactone and 10% glycolide.

Indications for Use

ORTHOCORD suture is indicated for use in general soft tissue approximation and/or ligation, including use in orthopedic surgeries.

Safety and Performance

The determination of substantial equivalence for this device was based on a detailed device description, and conformance to consensus and voluntary standards. Non-clinical laboratory testing was performed demonstrating that the device conformed to the USP monograph for absorbable sutures.

Based on the indications for use, technological characteristics, and comparison to predicate devices, the ORTHOCORD suture has been shown to be substantially equivalent to predicate devices under the Federal Food, Drug and Cosmetic Act.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Depuy Mitek % Ms. Kristine Christo Regulatory Affairs Project Lead 325 Paramount Drive Raynham, Massachusetts 02767

APR 23 2008

Re: K080918

Trade/Device Name: Orthocord #2-0 suture with or without needles

Regulation Number: 21 CFR 878.4840

Regulation Name: Absorbable polydioxanone surgical suture

Regulatory Class: II

Product Code: NEW, GAT Dated: March 13, 2008 Received: April 1, 2008

Dear Ms. Christo:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 – Ms. Kristine Christo

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Mark N. Melkerson

Mark M Milkerson

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

INDICATIONS FOR USE

Prescription Use	Orthocord #2-0 suture is indicated for use in	n general soft	tissue appro	oximation a	and/or ligation	on, includi
Prescription Use AND/OR Over-The-Counter Use (21 CFR 801 Subpart D) (21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IN NEEDED) (Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) Division of General, Restorative, and Neurological Devices	Orthocord #2-0 suture is indicated for use in	n general soft	tissue appro	oximation a	and/or ligatio	on, includi
Prescription Use AND/OR Over-The-Counter Use (21 CFR 801 Subpart D) (21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IN NEEDED) (Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) Division of General, Restorative, and Neurological Devices	Orthocord #2-0 suture is indicated for use in	n general soft	tissue appro	oximation a	and/or ligation	on, includi
AND/OR Over-The-Counter Use		n general soft	tissue appro	oximation a	and/or ligation	on, includi
rescription Use		n general soft	ussue appro	oximau o n a	and/or ligati	on, includi
rescription Use AND/OR Over-The-Counter Use art 21 CFR 801 Subpart D) (21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE INTEREDED) Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) Division of General, Restorative, and Neurological Devices						
(21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE DEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) Division of General, Restorative, and Neurological Devices						
(21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE DEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) Division of General, Restorative, and Neurological Devices						
(21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE DEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) Division of General, Restorative, and Neurological Devices						
(21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE DEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) Division of General, Restorative, and Neurological Devices						
(21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE DEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) Division of General, Restorative, and Neurological Devices						•
(21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE DEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) Division of General, Restorative, and Neurological Devices					•	
(21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE DEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) Division of General, Restorative, and Neurological Devices						
(21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE DEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) Division of General, Restorative, and Neurological Devices			•	•		
(21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE DEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) Division of General, Restorative, and Neurological Devices						
(21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE DEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) Division of General, Restorative, and Neurological Devices		•				
(21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE DEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) Division of General, Restorative, and Neurological Devices				·		
(21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE DIEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) Division of General, Restorative, and Neurological Devices					•	
(21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE DIEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) Division of General, Restorative, and Neurological Devices						
(21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE DEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) Division of General, Restorative, and Neurological Devices						
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IN IEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) Division of General, Restorative, and Neurological Devices		AND/OR				· .
Concurrence of CDRH, Office of Device Evaluation (ODE) Concurrence of CDRH, Office of CDRH, Office ODE (ODE) Concurrence of CDRH, Office of CDRH, Office ODE (ODE) Concurrence of CDRH, Office ODE (ODE) Concurrence of CDRH, Office ODE (ODE) Concurrence of CDRH, Office ODE (ODE) Concurrence of CDRH, ODE (ODE)	an 21 CFR 801 Suppart D)		(21	CFR 807 S	suppart C)	
Concurrence of CDRH, Office of Device Evaluation (ODE) Concurrence of CDRH, Office of CDRH, Office ODE (ODE) Concurrence of CDRH, Office of CDRH, Office ODE (ODE) Concurrence of CDRH, Office ODE (ODE) Concurrence of CDRH, Office ODE (ODE) Concurrence of CDRH, Office ODE (ODE) Concurrence of CDRH, ODE (ODE)	(PLEASE DO NOT WRITE BELOV	W THIS LIN	E-CONTI	NUE ON	ANOTHE	R PAGE I
(Division Sign-Off) Division of General, Restorative, and Neurological Devices Page 1 of					•	
(Division Sign-Off) Division of General, Restorative, and Neurological Devices Page 1 of		<u></u>			<u></u>	
(Division Sign-Off) Division of General, Restorative, and Neurological Devices	Concurrence of CDR	RH, Office of	Device Ev	valuation ((ODE)	
(Division Sign-Off) Division of General, Restorative, and Neurological Devices	\sim	Text RCO	July G	1 holen		
Division of General, Restorative. and Neurological Devices Page 1 of	(Division Ši	gn-Off)	U T	Borosid S. L. P. C.		
and Neurological Devices Page 1 of 1			Doctoro4:	WA:		
and Neurological Devices	•			V C ,	Page 1 o	of
10(k) Premarket Notification Shacillarm how (NO) 18 Confidential	and Neurole	ogical Dev	ices			
10(k) Premarket Notification Spacial sumbars (980918) Confidential						
TABLE A CONTRACT OF THE PARTICLE OF THE PARTIC	10/h) Pramarket Notificatesh Chacht	han K)8091	- 	Cont	fidential